Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Call to Action on COVID-19 Vaccinations and Patients with Cancer: Vaccinate. Monitor. Educate.

ESMO-Public-Policy-Webinars-1000x250px-Call-to-Action

The protection of cancer patients through immunisation against COVID-19 is a public health priority.

Recognising the urgent need for information on the topic of ‘COVID-19 vaccinations and patients with cancer’, ESMO organised a virtual meeting to launch a Call to Action for Member States to Vaccinate. Monitor. Educate. 

Please click here to see the list of over 40 organisations that have endorsed the ESMO Call to Action on COVID-19 Vaccinations and Patients with Cancer.

Read the ESMO editorial in Annals of Oncology entitled:

The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate

The ESMO Call to Action on COVID-19 Vaccinations and Patients with Cancer: Vaccinate. Monitor. Educate., has been translated into the following languages:

In the context of the Member States developing their vaccination strategies, the European Society for Medical Oncology (ESMO) would like to request the Member States to consider the following:

  1. Vaccinate all cancer patients in line with the WHO principles and objectives aiming to reduce deaths and disease burden. Patients with active disease or receiving anticancer treatment deserve an additional priority in case of limitations only.
  2. Diligently collect data via suitable studies and registries, to monitor the effects of vaccines in the vulnerable population, including patients with cancer and their immune response.
  3. Educate and instil confidence among the public and patients in receiving the vaccines and provide them with up-to-date information in lay language.

As healthcare professionals and patient advocacy organisations representing cancer patients and their families, our aim is to work together to ensure that the first principle of the WHO’s SAGE value framework for the allocation and prioritisation of immunisation is  adhered to: to reduce deaths and disease burden and protect those who most need protection.

During the event, leading experts from the World Health Organization, the European Commission, the European Medicines Agency, and the cancer patient community presented and discussed their views and strategies on the impact and importance of COVID-19 vaccinations in patients with a high-risk profile, including those with cancer.

ESMO Statements for Vaccination Against COVID-19 in Patients with Cancer

In addition to launching a Call to Action, ESMO has published a series of statements to address issues and concerns on immunising patients with cancer against COVID-19. The statements address vaccines under development and nearing approval, the incidence and severity of COVID-19 in cancer patients, the priority cancer patients should be given during the immunisation process, the ability of cancer patients to mount an immune response post vaccination, possible risks of interaction between the vaccine and anticancer therapies, and a 4-step process to develop a risk/benefit profile and identify subgroups of cancer patients for vaccination.

ESMO COVID-19 and Cancer Portal

Since the onset of the COVID-19 pandemic, ESMO has been at the forefront in providing a vast array of useful and informative resources for the cancer community through the ESMO COVID-19 and Cancer Portal.

The portal contains

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings